AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04106297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3970 oral solution
Description: GLPG3970 for oral administration
Study NCT04106297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral solution
Description: Placebo for oral administration
Study NCT04106297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral solution
Description: Placebo for oral administration
Study NCT04106297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3970 capsule
Description: GLPG3970 for oral administration
Study NCT04609943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1211163
Description: Participants will receive one of the drug doses of BAY1211163 solution three times per day (TID) by inhalation for seven days.
Study NCT02595892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Given IV
Study NCT02595892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given IV
Study NCT02595892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT02595892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT02595892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT03796650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: 50 g donor feces suspended in saline with added glycerol, administered by a enema kit.
Study NCT03796650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Peroral vancomycin 125 mg q.i.d. for ten days.
Study NCT02615600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lf-tRNS
Description: Low-frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): \<100Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4
Study NCT02331056 — intervention group
Intervention type: OTHER
Intervention: fluid loading
Description: Fluid loading at defined period~* 500ml colloid solution infusion at 20min after thorax open for 30min. 500ml colloid administration is a kind of routine procedure during pulmonary lobectomy in our hospital. We just control the fluid loading timing for hemodynamic parameter records.
Study NCT02331056 — intervention group
Intervention type: PROCEDURE
Intervention: thoracoscopic pulmonary lobectomy
Description: the patient group for scheduled thoracoscopic pulmonary lobectomy
Study NCT02331056 — intervention group
Intervention type: PROCEDURE
Intervention: thoracotomy
Description: the patient group for scheduled open pulmonary lobectomy
Study NCT02432443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor and pre-literacy program
Description: The program will run for 60 minutes once per week for 10 consecutive weeks and will consist of three components: direct FMS instruction, unstructured exploratory free-play, and an interactive storybook reading activity. The curriculum and teaching strategies to be used for the first two segments of our intervention have been successfully implemented in previous research to improve the motor skills of 4 year old children with autism (Bremer, Balogh, \& Lloyd, 2014). Specific strategies and books were selected from an existing evidence-based curriculum (Justice \& McGuinty, 2009). There will be active involvement of at least one parent in the direct instruction and reading components.
Study NCT02432443 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list Comparison
Description: The participants will not participate in the motor and pre-literacy program for 10 weeks after enrollment and will continue with their normal daily life without any intervention. After the experimental arm completes the motor and pre-literacy program, the wait-list group will receive the exact same motor and pre-literacy intervention.
Study NCT02825498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact force guided RFA
Description: Contact force guided RFA during Atrial Flutter ablation procedure.
Study NCT00829569 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intralipid +/- Omegaven
Description: Intralipid®: the 500 ml 20% Intralipid will be infused during a hyperinsulinemic clamp. Infusion rate will increase from 50 to 100 ml/hour the first 30 min and then continue at 100 ml/hour for the next 210 min, infusion duration 240 min (4 hours) in all.~Intralipid® + Omegaven®: In the 500 ml 20% Intralipid 100 ml will be replaced by 100 ml 10% Omegaven and infused during the hyperinsulinemic clamp as described for Intralipid only. Heparin (0.4 U/kg/min) will be added to both lipid emulsions.~Content of marine n-3 fatty acids in 100 ml Omegaven will be 1.25-2.82 g EPA and 1.44-3.09 g DHA (seasoning variations of n-3 fatty acids in fish oil).
Study NCT00236223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin + dexamethasone + ketamine
Description: Comparing analgesic effect of gabapentin 1200 mg + dexamethasone 8 mg + ketamine 0.15 mg/kg
Study NCT00236223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT00474812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Study NCT00474812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study NCT00474812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physiologic testing
Description: Correlative study
Study NCT00685230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antivenin Centruroides (scorpion) equine immune F(ab)2
Description: 3 vials of Alacramyn reconstitued in 50 ml of normal saline as a IV infusion over 10 minutes.
Study NCT00685230 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo reconstituted in 50 ml of normal saline administered over 10 min
Study NCT00619034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost, diclofenac and dorzolamide (eyedrops)
Description: 1 eyedrop twice daily in one week
Study NCT00619034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: dicolfenac eyedrops twice daily i one eye
Study NCT00619034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Description: dorzolamide eyedrops twice daily, in one eye for one week
Study NCT02873858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: smell and taste tests
Study NCT02873858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: smell and taste tests
Study NCT02586181 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D and Calcium
Description: a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate~1200 IE Vitamin D3 plus 800 mg Calcium Carbonate~Arm: Experimental: Vitamin D, Calcium, Vitamins B9, B6, B12~1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12
Study NCT02586181 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D, Calcium, Vitamins B9, B6, B12
Description: a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12
Study NCT01022060 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Renalof
Description: One Renalof tablet (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 weeks
Study NCT01022060 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One Placebo tablet (Orally administered) three time a day (just before each meal: breakfast, lunch and dinner), for 12 weeks
Study NCT03851835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Oral Solution
Description: Six doses of oral ondansetron (0.15mg/kg) to be administered q8h (every 8 hours) to a maximum of 3 times in a 24 hour period, are provided to the participant/caregiver for use after emergency department disposition (i.e. home use).
Study NCT03851835 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Six doses of oral placebo (0.15mg/kg) to be administered q8h (every 8 hours) to a maximum of 3 times in a 24 hour period, are provided to the participant/caregiver for use after emergency department disposition (i.e. home use).
Study NCT03241732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anti-inflammatory Diet
Description: Integrative diet that reduces saturated fats and carbohydrates and emphasizes proteins and omega-3 fats that help reduce inflammation and oxidative damage.
Study NCT03241732 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl Cysteine
Description: Intravenous and Oral n-acetyl cysteine
Study NCT03241732 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuro Emotive Technique
Description: Neuro Emotive Technique sessions
Study NCT03777306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ARM A EARLY INTERVENTION GROUP
Description: Post randomization, all patients will take baseline survey to assess their level of stress prior to starting the educational program During the educational interventions they will receive~* 1 video/picture/worksheet per week covering the topic to be covered.~* 1 phone/week by the Health Advisor, to discuss the topic for the week s/as their disease, stress and anxiety management, life organization, adherence skills, healthy eating and sleeping). Participant and the health advisor will also set up a Tiny Step to serve as a goal for the week .~* 3 emails/texts through the week, to remind about the topic covered, or to encourage them on their Tiny Step goal.~After 12 weeks on the program participants will re-take the surveys to assess the level of stress.
Study NCT03777306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ARM B DELAYED INTERVENTION GROUP
Description: The educational intervention is similar as in ARM A except that the participants will receive standard of care for the first 12 weeks post randomization and then begin the educational intervention
Study NCT02002598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered IV on days 1 and 2 with dose escalation up to 90 mg/m2 of each 28-day cycle.~Dose escalation is as follows:~-1 \| 60 mg/m2~1. \| 70 mg/m2~2. \| 70 mg/m2~3. \| 90 mg/m2~4. \| 90mg/m2~5. \| 90 mg/m2
Study NCT02002598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered IV on Days 1, 2, 8, 9, 15, and 16 every 28 days.~Dose Escalation is as follows:~-1 \| 27 mg/m2~1. \| 27 mg/m2~2. \| 36 mg/m2~3. \| 36 mg/m2~4. \| 45 mg/m2~5. \| 56 mg/m2
Study NCT02002598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered PO or IV, 20 mg, on 1, 2, 8, 9, 15, 16 and 22, 23 of each 28-day cycle.
Study NCT02202122 — intervention group
Intervention type: OTHER
Intervention: OSA Scoring
Description: Comparison of the preoperative OSA scoring (STOP-BANG, DES-OSA, P-SAP and OSA50) with the postoperative mortality at one month.
Study NCT03542812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Citrulline
Description: The L-citrulline will be procured in powder form and will be solubilized in sterile water to achieve a concentration of 50 mg/ml. Therefore, 3 ml/kg of the solubilized L-citrulline (50 mg/ml) will be administered per dose for the single-dose groups and the dose administered to the steady-state group will be determined from results from the single-dose studies.
Study NCT02977663 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: * Chest MRI during the MRI cerebral~* 2 tubes of blood taken during the medical visit
Study NCT04305834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO
Study NCT04555031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kalifilcon A lenses
Description: Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
Study NCT04555031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dalies Total 1
Description: Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
Study NCT04555031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Precision 1
Description: Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
Study NCT04555031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biotrue ONEday
Description: Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
Study NCT01422421 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intensive control
Description: use any medication to achieve systolic blood pressure less than 120mmHg and LDL cholesterol within 70-85mg/dl
Study NCT01422421 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard control
Description: use any medication to achieve systolic blood pressure less than 130mmHg and LDL cholesterol less than 100mg/dl
Study NCT02805881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurolief system
Description: Non-invasive cephalic neurostimulation device
Study NCT03368638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy intervention
Description: Double knee to chest stretches, hip extension mobilization, neural mobilizations, home exercises program
Study NCT03463161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (200mg/kg) given by intravenous infusion every 3 weeks.
Study NCT03463161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat (100mg) taken by mouth twice a day.
Study NCT05132192 — intervention group
Intervention type: PROCEDURE
Intervention: living donor liver transplantation
Description: Living donor liver transplantation
Study NCT05132192 — intervention group
Intervention type: PROCEDURE
Intervention: Thrombectomy or interposition graft
Description: Portal flow restoration due to PVT in any manner
Study NCT02372136 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Individualized Nutrition
Description: Intake of macronutrients (protein, fat, and carbohydrate) will be individualized every day by adding one or more macronutrients to human milk based on daily measurements using near-infrared analysis.~In patients receiving less milk than 140 ml x kg-1 x day-1 fortification of human milk will be adjusted to reach at least the average concentrations of protein, fat, and carbohydrate in donor's milk (Wojcik. J Am Diet Assoc. 2009 Jan;109:137-40) and 20 cal/oz as provided by the Mother's Milk Bank of North Texas.~In those receiving at least 140 ml x kg-1 x day-1 of milk at 24 cal/oz fortification will be adjusted to meet recent guidelines from the the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition (ESPGHAN) (Agostoni et al. J Pediatr Gastroenterol Nutr. 2010 Jan;50:85-91).
Study NCT02372136 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Optimized nutrition
Description: Milk fortification will be based on current recommendations and optimized by adjustment of nutrients once a week based on blood levels of urea nitrogen (corrected for serum creatinine level) and albumin and velocity of growth (weight and length).
Study NCT02372136 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Optimized nutrition
Description: Milk fortification will be based on current recommendations and optimized by adjustment of nutrients once a week based on blood levels of urea nitrogen (corrected for serum creatinine level) and albumin and velocity of growth (weight and length).
Study NCT02704468 — intervention group
Intervention type: OTHER
Intervention: CAVI and FGF-21
Description: FGf-21 and CAVI was measured in renal transplant patients group and study correlation with arterial stiffness
Study NCT02075541 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTHi-10-AS01E
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Study NCT02075541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl Placebo
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Study NCT01964885 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IQP-AS-105
Study NCT01964885 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04305834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03269422 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-based image-guided, intensity-modulated radiotherapy
Description: Patients will receive a standard dose of 8 Gy/fraction for five fractions for a total dose of 40 Gy to the prostate with a simultaneously delivered boost of 9 Gy for five fractions (clinically non-standard dose of 45 Gy total) to a single dominant lesion with a maximum dimension of at least 0.5 cm as determined on pre-treatment diagnostic T2 MRI imaging.
Study NCT02252380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial ExAblate System
Description: MR Guided Focused Ultrasound
Study NCT02168868 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: A blood sample (5 mL) will be collected.
Study NCT05235204 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal of Foley Catheter 2 to 3 days post Colovesical Fistula (CVF) repair surgery
Description: According to review of internal clinical practices, the average duration of catheterization after Colovesical Fistula (CVF) repair is 10.8 days after CVF repair. The intervention in this study removes the Foley Catheter at 2 to 3 days post CVF repair.
Study NCT03954795 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP
Description: Classic TAP block performed through the petit triangle (the anterior axillary line and iliac crest)
Study NCT03954795 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OSTAP
Description: Modified TAP (OSTAP) block performed from the medial of linea semilunaris applying local anesthetic to the area between xiphoid and anterior iliac crest.
Study NCT04466995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: manometer
Description: cuff pressure to be measured with manometer
Study NCT04466995 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: manometer
Description: cuff pressure to be measured with manometer
Study NCT01088828 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI) of calf and foot
Description: Detailed 3-D comparison of MRI scans of children with clubfoot and controls without clubfoot in utero, in untreated infants and in older children who have been treated.
Study NCT02168868 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stool Sample Collection
Description: Subjects will be provided a dry, plastic, screw-top specimen container and will be asked to collect a stool sample at home.
Study NCT02168868 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Sample Collection
Description: Subjects will be provided a dry, plastic, screw-top specimen container and will be asked to collect a urine sample at home.
Study NCT01632670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: The music played will be by MusiCure, by Niels Eje (slow, relaxing music designed for therapeutic use), and will be played from an audio pillow beneath the patient's head.
Study NCT03698812 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Colonoscope
Description: take off specimen
Study NCT00974376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin 1200mg/day
Description: gabapentin 1200mg/day for 12 weeks
Study NCT00974376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1200mg/day of placebo for 12 weeks
Study NCT00974376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manual-guided behavioral counseling
Description: Standardized manual-guided behavioral counseling performed 1 time per week for 12 weeks in conjunction with study drug or placebo.
Study NCT00974376 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Manual-guided behavioral counseling
Description: Standardized manual-guided behavioral counseling performed 1 time per week for 12 weeks in conjunction with study drug or placebo.
Study NCT04230187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI plus Bevacizumab
Description: Bevacizumab (5 mg/kg on day 1) plus mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 8 cycles and followed by bevacizumab and fluoropyrimidine based maintence treatment
Study NCT04230187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6 Plus Bevacizumab
Description: mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 8 cycles and followed by bevacizumab and fluoropyrimidine based maintence treatment
Study NCT03341689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Psilocybin
Description: 0.143 mg/kg psilocybin capsule